Global Gastroparesis Drugs Market

Global Gastroparesis Drugs Market Size Insights Forecasts to 2035

• The Global Gastroparesis Drugs Market Size Was valued at USD 6.8 Billion in 2024
• The Global Gastroparesis Drugs Market Size is Expected to Grow at a CAGR of around 4.21% from 2025 to 2035
• The Worldwide Gastroparesis Drugs Market Size is Expected to Reach USD 10.7 Billion by 2035
• Asia-Pacific is expected to grow the fastest during the forecast period.

According to a research report published by Decisions Advisors and Consulting, The Global Gastroparesis Drugs Market Size Was Worth Around USD 6.8 Billion In 2024 And Is Predicted To Grow To Around USD 10.7 Billion By 2035 With A Compound Annual Growth Rate (CAGR) Of 4.21% From 2025 To 2035. The market expansion is driven by multiple factors which include the rising occurrence of diabetic gastroparesis and the progress in drug development technologies and the growing understanding of diabetes among both healthcare workers and patients and the increasing financial resources dedicated to healthcare and the expanding clinical trials and the rising number of patients with diabetes and Parkinson’s disease and the backing provided by regulatory authorities.

 

Market Overview

The Global Gastroparesis Drugs Market Size refers to the industry that develops and sells medications which enhance gastric motility and alleviate nausea and vomiting while treating delayed gastric emptying in patients with gastroparesis. Additionally, the gastroparesis drugs market is currently experiencing notable developments driven by a combination of factors which include an increasing prevalence of gastroparesis and a growing awareness of the condition among healthcare professionals and patients. Pharmaceutical companies are currently developing new treatments which will enable them to solve the specific problems that this disorder presents to their patients. The treatment options for gastroparesis will undergo transformation because healthcare systems focus on developing treatment methods which provide personalized care to patients. The collaboration between healthcare providers and researchers and regulatory bodies creates an environment which supports the development of new drugs and their delivery systems. The gastroparesis drugs market will undergo a transformation towards integrated treatment approaches which combine medication procedures with patient education and dietary treatment methods. This comprehensive treatment method will improve patient outcomes because it treats all aspects of their medical condition. Increased awareness will result in dedicated funds which will support training initiatives and patient assistance programs for healthcare providers and their patients which will enhance control over gastroparesis and its related symptoms.

 

Report Coverage

This research report categorizes the gastroparesis drugs market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the gastroparesis drugs market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the gastroparesis drugs market. 

 

Driving Factors

The market expansion is increasing because businesses are developing more products and introducing different product variations. The market is expanding because pharmaceutical research and development (R&D) investments are increasing to develop safer and more effective gastroparesis treatments. The gastroparesis drug market has gained new opportunities through high-throughput screening and computational personalized medicine which allow for rapid identification of potential drug candidates. The market expansion is driven by new drug delivery systems which include extended-release formulations and innovative drug delivery technologies that improve medication administration and absorption.

 

Restraining Factors

The Global Gastroparesis Drugs Market Size faces restraints due to limited approved therapies and adverse drug side effects and high treatment costs and strict regulatory requirements and the absence of long-term efficacy data for upcoming pipeline drugs.

 

Market Segmentation

The gastroparesis drugs market share is classified into disease type and drug class.

 

• The diabetic gastroparesis segment dominated the market in 2024, approximately 47% and is projected to grow at a substantial CAGR during the forecast period.

Based on the disease type, the gastroparesis drugs market is divided into diabetic gastroparesis, idiopathic gastroparesis, post-surgical gastroparesis, and others. Among these, the diabetic gastroparesis segment dominated the market in 2024, approximately 47% and is projected to grow at a substantial CAGR during the forecast period. The global diabetes epidemic continues to increase because of the rising number of people who develop type 1 and type 2 diabetes. Long-term hyperglycemia causes damage to the vagus nerve which results in the medical condition of delayed gastric emptying. The segment experiences substantial growth because of three factors which include increased public understanding of diabetes, improved diagnostic capabilities, and rising needs for diabetic patient treatment.

 

• The prokinetic agents segment accounted for the largest share in 2024, approximately 52% and is anticipated to grow at a significant CAGR during the forecast period.

Based on the drug class, the gastroparesis drugs market is divided into prokinetic agents, antiemetic agents, botulinum toxin injections. Among these, the prokinetic agents segment accounted for the largest share in 2024, approximately 52% and is anticipated to grow at a significant CAGR during the forecast period. Prokinetic agents are a category of drugs that boost the contractions of stomach muscles, which in turn helps improve the overall movement of the stomach. The medical staff uses these medications to treat patients who experience gastroparesis, which produces symptoms of nausea and vomiting while disrupting their ability to digest food. Prokinetic agents function as essential medications for treating gastroparesis because they provide treatment for the condition's fundamental cause. The researchers studied these medications because they wanted to test their safety and effectiveness for critical patients who received enteral nutrition, and the study showed that the drugs successfully decreased feeding intolerance in those patients.

Regional Segment Analysis of the Gastroparesis Drugs Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America is anticipated to hold the largest share of the gastroparesis drugs market over the predicted timeframe.

North America is anticipated to hold the largest share of the gastroparesis drugs market over the predicted timeframe. The growing rate of gastroparesis cases especially within the diabetic population has created a strong need for effective treatment options. The high incidence of diabetes is a major contributing factor, as diabetic gastroparesis is a common complication. The gastroparesis drugs market develops through its recent advancements which include high-throughput screening and new drug delivery systems that improve the efficacy and safety of gastroparesis medications. The region benefits from its strong healthcare system and major research and development funding which enables rapid development of new medical treatments. The increasing knowledge of healthcare professionals and patients about gastroparesis and its management is driving market growth because it leads to faster diagnosis and earlier treatment of the condition.

 

Asia-Pacific is expected to grow at a rapid CAGR in the gastroparesis drugs market during the forecast period. The high diabetes rates and the fast urban growth together with better diagnostic systems. The regulatory authorities in South Korean markets now permit reimbursement for new acid-suppressive medications that doctors can use together with prokinetic drugs, which indicates that the market has started to accept innovative gastrointestinal treatment methods. The pharmaceutical industry forms alliances such as the Lupin–Takeda partnership to distribute vonoprazan in India because international companies value local relationships to handle their pricing and distribution challenges.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the gastroparesis drugs market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Abbott Laboratories
• AbbVie Inc.
• AstraZeneca PLC
• Bayer AG
• Cipla Ltd.
• Evoke Pharma
• Pfizer Inc.
• Salix Pharmaceuticals
• Takeda Pharmaceutical, Inc.
• Teva Pharmaceutical Inc.
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

 

• In January 2025, Entero Therapeutics agreed to a reverse merger with Journey Therapeutics to form a Nasdaq-listed entity that was focused on gastrointestinal diseases, including capeserod for gastroparesis.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Decisions Advisors has segmented the gastroparesis drugs market based on the below-mentioned segments: 

 

Global Gastroparesis Drugs Market, By Disease Type

• Diabetic Gastroparesis
• Idiopathic Gastroparesis
• Post-surgical Gastroparesis
• Others

 

Global Gastroparesis Drugs Market, By Drug Class

• Prokinetic Agents
• Antiemetic Agents
• Botulinum Toxin Injections

 

Global Gastroparesis Drugs Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  •  South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa

 

Frequently Asked Questions (FAQ)

 

1. What is the projected growth of the global gastroparesis drugs market?

A: The market is projected to grow from USD 6.8 billion in 2024 to USD 10.7 billion by 2035, registering a CAGR of 4.21% during 2025–2035.

 

2. Which disease segment dominates the market?

A: Diabetic gastroparesis dominates with approximately 47% market share in 2024, driven by rising global diabetes prevalence, increasing awareness, improved diagnostics, and growing treatment demand among diabetic patients.

 

3. Which drug class holds the largest market share?

A: Prokinetic agents lead with around 52% share in 2024, as they directly improve gastric motility and treat the root cause of delayed gastric emptying.

 

4. What are the major market growth drivers?

A: Key drivers include rising diabetes cases, increasing R&D investments, advancements in drug delivery systems, expanding clinical trials, personalized medicine technologies, and regulatory support for innovative gastrointestinal therapies.